182 related articles for article (PubMed ID: 17448875)
21. Combretastatin-induced hypertension and the consequences for its combination with other therapies.
Busk M; Bohn AB; Skals M; Wang T; Horsman MR
Vascul Pharmacol; 2011; 54(1-2):13-7. PubMed ID: 21040805
[TBL] [Abstract][Full Text] [Related]
22. In vivo near-infrared spectroscopy and magnetic resonance imaging monitoring of tumor response to combretastatin A-4-phosphate correlated with therapeutic outcome.
Zhao D; Chang CH; Kim JG; Liu H; Mason RP
Int J Radiat Oncol Biol Phys; 2011 Jun; 80(2):574-81. PubMed ID: 21345614
[TBL] [Abstract][Full Text] [Related]
23. Uniform Combretastatin-induced Effect on Monocytes and Neutrophils in Peripheral Blood but Not in Tumors.
Bohn AB; Brems-Eskildsen AS; Møller BK; Horsman MR
Anticancer Res; 2015 May; 35(5):2559-64. PubMed ID: 25964530
[TBL] [Abstract][Full Text] [Related]
24. Transcatheter Arterial Embolization Combined with Anti-vascular Agent Combretastatin A4 Phosphate Inhibits Growth and Vascularization of Liver Tumor in an Animal Model.
Zhao H; Wu ZZ; Ren Q; Wu JJ; Wang Y; Feng JW; Rao M; Deng Q; Hu HY
Curr Med Sci; 2022 Dec; 42(6):1240-1247. PubMed ID: 36462132
[TBL] [Abstract][Full Text] [Related]
25. Preclinical evaluation of vascular-disrupting agents in Ewing's sarcoma family of tumours.
Dalal S; Burchill SA
Eur J Cancer; 2009 Mar; 45(4):713-22. PubMed ID: 19136249
[TBL] [Abstract][Full Text] [Related]
26. Tumor antivascular effects of radiotherapy combined with combretastatin a4 phosphate in human non-small-cell lung cancer.
Ng QS; Goh V; Carnell D; Meer K; Padhani AR; Saunders MI; Hoskin PJ
Int J Radiat Oncol Biol Phys; 2007 Apr; 67(5):1375-80. PubMed ID: 17275203
[TBL] [Abstract][Full Text] [Related]
27. Evaluation of combretastatin A-4 prodrug in a non-Hodgkin's lymphoma xenograft model: preclinical efficacy.
Nabha SM; Mohammad RM; Wall NR; Dutcher JA; Salkini BM; Pettit GR; Al-Katib AM
Anticancer Drugs; 2001 Jan; 12(1):57-63. PubMed ID: 11272287
[TBL] [Abstract][Full Text] [Related]
28. Combretastatin A4 phosphate: background and current clinical status.
Young SL; Chaplin DJ
Expert Opin Investig Drugs; 2004 Sep; 13(9):1171-82. PubMed ID: 15330748
[TBL] [Abstract][Full Text] [Related]
29. The development and use of vascular targeted therapy in ovarian cancer.
Chase DM; Chaplin DJ; Monk BJ
Gynecol Oncol; 2017 May; 145(2):393-406. PubMed ID: 28238563
[TBL] [Abstract][Full Text] [Related]
30. Vascular effects dominate solid tumor response to treatment with combretastatin A-4-phosphate.
Lunt SJ; Akerman S; Hill SA; Fisher M; Wright VJ; Reyes-Aldasoro CC; Tozer GM; Kanthou C
Int J Cancer; 2011 Oct; 129(8):1979-89. PubMed ID: 21154772
[TBL] [Abstract][Full Text] [Related]
31. Cardiovascular safety profile of combretastatin a4 phosphate in a single-dose phase I study in patients with advanced cancer.
Cooney MM; Radivoyevitch T; Dowlati A; Overmoyer B; Levitan N; Robertson K; Levine SL; DeCaro K; Buchter C; Taylor A; Stambler BS; Remick SC
Clin Cancer Res; 2004 Jan; 10(1 Pt 1):96-100. PubMed ID: 14734457
[TBL] [Abstract][Full Text] [Related]
32. Activity of the vascular targeting agent combretastatin A-4 disodium phosphate in a xenograft model of AIDS-associated Kaposi's sarcoma.
Rojiani AM; Li L; Rise L; Siemann DW
Acta Oncol; 2002; 41(1):98-105. PubMed ID: 11990526
[TBL] [Abstract][Full Text] [Related]
33. Treatment of rodent liver tumor with combretastatin a4 phosphate: noninvasive therapeutic evaluation using multiparametric magnetic resonance imaging in correlation with microangiography and histology.
Wang H; Sun X; Chen F; De Keyzer F; Yu J; Landuyt W; Vandecaveye V; Peeters R; Bosmans H; Hermans R; Marchal G; Ni Y
Invest Radiol; 2009 Jan; 44(1):44-53. PubMed ID: 19034028
[TBL] [Abstract][Full Text] [Related]
34. Combretastatins: In vitro structure-activity relationship, mode of action and current clinical status.
Jaroch K; Karolak M; Górski P; Jaroch A; Krajewski A; Ilnicka A; Sloderbach A; Stefański T; Sobiak S
Pharmacol Rep; 2016 Dec; 68(6):1266-1275. PubMed ID: 27686966
[TBL] [Abstract][Full Text] [Related]
35. Early effects of combretastatin A4 phosphate assessed by anatomic and carbogen-based functional magnetic resonance imaging on rat bladder tumors implanted in nude mice.
Thomas CD; Walczak C; Kaffy J; Pontikis R; Jouanneau J; Volk A
Neoplasia; 2006 Jul; 8(7):587-95. PubMed ID: 16867221
[TBL] [Abstract][Full Text] [Related]
36. Differential sensitivity of two adenocarcinoma xenografts to the anti-vascular drugs combretastatin A4 phosphate and 5,6-dimethylxanthenone-4-acetic acid, assessed using MRI and MRS.
Beauregard DA; Pedley RB; Hill SA; Brindle KM
NMR Biomed; 2002 Apr; 15(2):99-105. PubMed ID: 11870905
[TBL] [Abstract][Full Text] [Related]
37. Preclinical evaluations of therapies combining the vascular targeting agent combretastatin A-4 disodium phosphate and conventional anticancer therapies in the treatment of Kaposi's sarcoma.
Li L; Rojiani AM; Siemann DW
Acta Oncol; 2002; 41(1):91-7. PubMed ID: 11990525
[TBL] [Abstract][Full Text] [Related]
38. Oxi4503, a novel vascular targeting agent: effects on blood flow and antitumor activity in comparison to combretastatin A-4 phosphate.
Hua J; Sheng Y; Pinney KG; Garner CM; Kane RR; Prezioso JA; Pettit GR; Chaplin DJ; Edvardsen K
Anticancer Res; 2003; 23(2B):1433-40. PubMed ID: 12820406
[TBL] [Abstract][Full Text] [Related]
39. A poly(l-glutamic acid)-combretastatin A4 conjugate for solid tumor therapy: Markedly improved therapeutic efficiency through its low tissue penetration in solid tumor.
Liu T; Zhang D; Song W; Tang Z; Zhu J; Ma Z; Wang X; Chen X; Tong T
Acta Biomater; 2017 Apr; 53():179-189. PubMed ID: 28167300
[TBL] [Abstract][Full Text] [Related]
40. Vascular disrupting effects of combretastatin A4 phosphate on murine endometriotic lesions.
Feng D; Menger MD; Laschke MW
Fertil Steril; 2013 Nov; 100(5):1459-67. PubMed ID: 23993929
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]